Raptiva
(efalizumab)PreclinicalMonoclonal antibody
RocheEfalizumab was used to treat moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches on the skin. It works by suppressing the immune system to reduce inflammation and improve skin appearance.[1] Raptiva is currently being investigated across 3 indications[3], with its most advanced program in Preclinical.[1]
Raptiva is one of 77 small molecule programs targeting Psoriasis Vulgaris. It is currently in Preclinical.
3
Indications
23
Total Trials
0
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Neoral
NovartisApproved
Medrol
PfizerApproved
Selzentry
GSKApproved
Nipent
PfizerApproved
Defitelio
Jazz PharmaceuticalsApproved
Olumiant
Eli LillyApproved
Gleevec
NovartisApproved
Qvar
SSchering-Plough
Approved
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis10 trials
Show 7 more trials
Diabetic Macular Edema1 trial
9 more indications
Kidney Transplant1 trial
Psoriatic Arthritis1 trial
Efficacy and Safety1 trial
Graft Versus Host Disease1 trial
De Novo Renal Transplantation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for efalizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]